OncoC4, Inc. appointed Steve Chen, JD, PhD, as General Counsel.
Published
Signal category
People
Quote
“We are pleased to announce the appointment of Steve Chen, JD, PhD, as General Counsel.”
— OncoC4, Inc. team
Company
OncoC4, Inc.
Scientific Discoveries Drive Explosive Immunotherapy
- Industry
- Biotechnology Research
- Location
- Rockville, US
- Company size
- 69 employees
Based in Rockville, Maryland, OncoC4 is a privately held, late clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biologics for the potential treatment of cancer. Its lead clinical candidate is BNT316/ONC-392, a next generation anti-CTLA-4 antibody that is designed to allow CTLA-4 to recycle and maintain its protective function against autoimmune diseases while enhancing anti-tumor activity at the same time. In addition, OncoC4 has a pipeline of potentially first-in-class preclinical product candidates focusing on the CD24-Siglecs cancer immune evasion pathway.
Founded 2020